The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA
Abstract
PURPOSE: To evaluate the efficacy of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the treatment of diabetic macular edema. METHODS: This prospective, consecutive, noncomparative case series included 51 consecutive patients (26 females and 25 males; mean age, 64 years) with diffuse diabetic macular edema. Inclusion criteria were determined independently of the size of edema, retinal thickness, visual acuity, age, metabolic control, type of diabetes, or previous treatments beyond a 6-month period. At each visit, patients underwent complete eye examination, including determination of best-corrected visual acuity, slit-lamp examination, intraocular pressure measurement, stereoscopic biomicroscopy of the macula, retinal thickness measurement by optical coherence tomography, fluorescein angiography, and fundus photography. After written informed consent was obtained, all patients were treated with a 0.05-mL injection containing 1.25 mg of bevacizumab. RESULTS: All patients completed 6 weeks of follow-up; 23 (45%) completed 12 weeks of follow-up. Sixteen patients (70%) had received at least two intravitreal injections. All patients had undergone previous treatments, such as focal laser therapy (35%), full-scatter panretinal laser therapy (37%), vitrectomy (12%), and intravitreal injection of triamcinolone (33%). The mean diameter of the foveal avascular zone was 503 micro m, with 49% with values of >500 micro m. At baseline, mean visual acuity +/- SD was 25.88 +/- 14.43 ETDRS letters (0.86 +/- 0.38 logMAR of Snellen letters). Mean central retinal thickness by optical coherence tomography +/- SD was 501 +/- 163 micro m (range, 252-1,031 micro m). Mean visual acuity +/- SD increased to 0.75 +/- 0.37 logMAR of Snellen letters at 6 weeks after injection (P = 0.001), with some regression to 0.84 +/- 0.41 logMAR of Snellen letters after 12 weeks. Changes in ETDRS letters were not significant throughout follow-up. Mean retinal thickness +/- SD decreased to 425 +/- 180 micro m at 2 weeks (P = 0.002), 416 +/- 180 micro m at 6 weeks (P = 0.001), and 377 +/- 117 micro m at 12 weeks (P = 0.001). Changes of retinal thickness and visual acuity correlated weakly (r = -0.480 and P = 0.03 at 6 weeks; r = -0.462 and P = 0.07 at 12 weeks). The increase of visual acuity after 6 weeks as measured by ETDRS charts could be predicted best by baseline visual acuity. No other factors investigated, such as age, thickness by optical coherence tomography, or previous treatments, were predictive for the increase in visual acuity. CONCLUSION: Even in cases of diffuse diabetic macular edema not responding to previous treatments such as photocoagulation, intravitreal injection of triamcinolone, or vitrectomy, improvement of visual acuity and decrease of retinal thickness could be observed after intravitreal injection of bevacizumab. Although our follow-up period was too short to provide specific treatment recommendations, the short-term results encourage further prospective studies with different treatment groups and longer follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,061
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Early Photocoagulation for Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38011-7 · Cited by 1,259
A central role for inflammation in the pathogenesis of diabetic retinopathy
Joussen, A. M., Poulaki, V., Le, M. L., Koizumi, K., Esser, C., Janicki, H., Schraermeyer, U., Kociok, N., Fauser, S., Kirchhof, B., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-1476fje · Cited by 1,176
Cited by
Overview of Epidemiologic Studies of Diabetic Retinopathy
Kobrin Klein, B. E. (2007) · Ophthalmic Epidemiology · doi:10.1080/09286580701396720 · Cited by 734
Diabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
Michaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C. J., Xing, W., Egan, C., Peto, T., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.045 · Cited by 521
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.05.062 · Cited by 451
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Metadata
- Authors
- HARITOGLOU, C., KOOK, D., NEUBAUER, A., WOLF, A., PRIGLINGER, S., STRAUSS, R., GANDORFER, A., ULBIG, M., & KAMPIK, A.
- Venue
- Retina
- Published
- 2006-11
- Volume
- 26
- Issue
- 9
- Pages
- 999-1005
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2011046688
- Cited by
- 453
- References
- 29
- FWCI
- 43.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA. https://app.cochat.ai/papers/10.1097/01.iae.0000247165.38655.bf
- The paper
- HARITOGLOU, C., KOOK, D., NEUBAUER, A., WOLF, A., PRIGLINGER, S., STRAUSS, R., GANDORFER, A., ULBIG, M., & KAMPIK, A. (2006). INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA. Retina. https://doi.org/10.1097/01.iae.0000247165.38655.bf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.